heart failure during imatinib therapy. 10 Of these patients, 13 had received prior treatment with cardiotoxic drugs and likely had preexisting conditions predisposing them to congestive heart failure. High-Dose Imatinib: Most patients retain variable
Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler
Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler and Furhan Yunus
. High-Dose Imatinib Most patients retain variable levels of residual molecular disease at the 400-mg dose of imatinib. Several studies have evaluated the efficacy of high-dose imatinib in patients with newly diagnosed CML. 25 - 27 Imatinib dosed at
Michael Deininger
leukemia . Clin Cancer Res 2003 ; 9 : 160 - 166 . 13 Cortes J Giles F O'Brien S . Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha . Blood
Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz and Meir Wetzler
. 63 Castagnetti F Palandri F Amabile M . Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party . Blood 2009 ; 113 : 3428
Stephen Harnicar
Hematologic Diseases (GIMEMA 021/ELN) high-dose imatinib trials. 11 , 12 Standard-dose imatinib (400 mg daily) was compared with high-dose imatinib (800 mg daily) in both trials. A recent update of the TOPS study reported no significant difference between the
Grant A. McArthur
. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial . Lancet 2004 ; 364 : 1127 – 1134 . 44. Zalcberg JR Verweij J Casali PG . Outcome of patients with advanced gastro-intestinal stromal tumours
Andrew Wagner
gastrointestinal stromal tumours with high-dose imatinib: randomised trial . Lancet 2004 ; 364 : 1127 – 1134 . 48. Rankin C Mehren MV Blanke C . Dose effect of imatinib (IM) in patients (pts) with metastatic GIST—phase III Sarcoma Group Study S0033
Lucas Vieira dos Santos, João Paulo Lima, Kathia Cristina Abdalla, Arinilda Campos Bragagnoli, Florinda Almeida Santos, Alexandre dos Anjos Jácome and Fabiano Elias Porto
with a metastatic gastrointestinal stromal tumor . N Engl J Med 2001 ; 344 : 1052 – 1056 . 5. Verweij J Casali PG Zalcberg J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O’Donnell, Alberto S. Pappo, I. Benjamin Paz, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman and Hema Sundar
and death. 14 A meta-analysis of the EORTC 62005 and SWOG S0033/CALGB 150105 phase III trials that randomized 1640 patients with advanced GIST to standard-dose (400 mg/d) or high-dose imatinib (800 mg/d) showed a PFS benefit for patients with KIT
Paul J. Shami
observed in the IRIS study. High-Dose Imatinib Two randomized trials were conducted comparing high-dose and standard-dose imatinib in the treatment of CP-CML. The Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study randomized 476
